PALOMA-3

Study Name:
A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Study Dates:
August 5, 2022 - August 1, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Janssen Research & Development, LLC

Sponsors:

Janssen Research & Development, LLC

Contact:

Phone: 1-844-434-4210
Email: Participate-In-This-Study@its.jnj.com

ClinicalTrails.gov Identifier:
NCT05388669

Register for Trial